Efficacy and safety of prothrombin complex concentrate for vitamin K antagonist-associated intracranial hemorrhage: a systematic review and meta-analysis

被引:10
作者
Pan, Rui [1 ]
Cheng, Jinping [2 ]
Lai, Kelin [1 ]
Huang, Qing [3 ]
Wu, Hui [1 ]
Tang, Yamei [2 ]
机构
[1] Huizhou Hlth Sci Polytech, Dept Nursing, Huizhou, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Neurol, Guangzhou 510120, Guangdong, Peoples R China
[3] Huizhou Hlth Sci Polytech, Dept Basic Courses, Huizhou, Guangdong, Peoples R China
基金
国家重点研发计划;
关键词
Intracranial hemorrhage; Vitamin K antagonists; Prothrombin complex concentrate; Meta-analysis; FRESH-FROZEN PLASMA; INTERNATIONAL NORMALIZED RATIO; FACTOR-IX COMPLEX; INTRACEREBRAL HEMORRHAGE; ANTICOAGULATION REVERSAL; WARFARIN; GUIDELINES; MANAGEMENT; COAGULOPATHY; ENLARGEMENT;
D O I
10.1007/s10072-019-3726-x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Prothrombin complex concentrate (PCC) is the treatment of choice in vitamin K antagonist-associated intracranial hemorrhage (VKA-ICH). However, the efficiency and safety associated with their use remain unclear. Aims This study aimed to assess the current evidence of the clinical outcomes in patients with VKA-ICH treated with or without PCC. Summary of review A meta-analysis was conducted. Two randomized controlled trials and 19 observational studies were included. PCC use demonstrated a significant increased likelihood of international normalized ratio (INR) normalization (OR=3.76; 95% CI 1.74-8.12), shortened time to INR correction (MD=-1.30; 95% CI -2.08 to -0.53) and reduction of hematoma expansion (HE) rate (OR=0.37; 95% CI 0.23-0.60). Although PCC use revealed a statistical reduction at 30-day mortality (OR=0.62; 95% CI 0.50-0.78), the result was inconsistent with mortality at discharge (OR=1.03; 95% CI 0.68-1.57) and 90-day follow-up (OR=0.50; 95% CI 0.24-1.07), both of which yielded no significant difference. When subgroup analyses were performed focus on PCC only treatment with FFP, no statistically significant difference was observed in 30-day mortality (OR=0.43; 95% CI 0.11-1.71) as well. Besides, significant difference was not found in neurologic improvement at discharge (OR=1.85; 95% CI 0.32-10.75), 30-day follow-up (OR=3.00; 95% CI 0.93-9.70), or 90-day follow-up (OR=1.55; 95% CI 0.84-2.86). No statistically significant difference was noted in the risk of thromboembolism following PCC administration (OR=0.61; 95% CI 0.23-1.63). Conclusions PCC use for VKA-ICH reversal was associated with a significant reduction in INR and HE rate, without an increased risk of thromboembolic events. However, this reduction was not associated with improvement in neurologic deficits or overall survival. Well-designed randomized trials with special considerations to the aspect are necessary.
引用
收藏
页码:813 / 827
页数:15
相关论文
共 50 条
[41]   Evaluation of a Fixed, Weight-Based Dose of 3-Factor Prothrombin Complex Concentrate Without Adjunctive Plasma Following Warfarin-Associated Intracranial Hemorrhage [J].
Mohrien, Kerry M. ;
Jones, G. Morgan ;
Boucher, Andrew B. ;
Elijovich, Lucas .
NEUROCRITICAL CARE, 2014, 21 (01) :67-72
[42]   Efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients (≥80 years of age) with atrial fibrillation: systematic review and meta-analysis [J].
Kang, Fengguang ;
Su, Lijun ;
Fan, Shuke ;
Lv, Lifen ;
Luo, Biru .
INTERNAL MEDICINE JOURNAL, 2023, 53 (09) :1524-1532
[43]   Activated Prothrombin Complex Concentrate Versus 4-Factor Prothrombin Complex Concentrate for Vitamin K-Antagonist Reversal [J].
Rowe, A. Shaun ;
Dietrich, Scott K. ;
Phillips, John W. ;
Foster, Kaci E. ;
Canter, Joshua R. .
CRITICAL CARE MEDICINE, 2018, 46 (06) :943-948
[44]   Vitamin K antagonist reversal strategies: Systematic review and network meta-analysis from the AABB [J].
Pagano, Monica B. ;
Foroutan, Farid ;
Goel, Ruchika ;
Allen, Elizabeth S. ;
Cushing, Melissa M. ;
Garcia, David A. ;
Hopkins, Courtney K. ;
Klein, Kimberly ;
Raval, Jay S. ;
Cohn, Claudia S. .
TRANSFUSION, 2022, 62 (08) :1652-1661
[45]   Safety of a Four-factor Prothrombin Complex Concentrate Versus Plasma for Vitamin K Antagonist Reversal: An Integrated Analysis of Two Phase IIIb Clinical Trials [J].
Milling, Truman J., Jr. ;
Refaai, Majed A. ;
Sarode, Ravi ;
Lewis, Brandon ;
Mangione, Antoinette ;
Durn, Billie L. ;
Harman, Amy ;
Lee, Martin L. ;
Goldstein, Joshua N. .
ACADEMIC EMERGENCY MEDICINE, 2016, 23 (04) :466-475
[46]   Risk factors for antiplatelet drug-associated intracranial hemorrhage: a systematic review and meta-analysis [J].
Zeng, Zhiwei ;
Chen, Jiana ;
Chen, Mingrong ;
Ma, Fuxin ;
Lv, Meina ;
Zhang, Jinhua .
NEUROLOGICAL SCIENCES, 2022, 43 (12) :6761-6769
[47]   Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate [J].
Majeed, Ammar ;
Meijer, Karina ;
Larrazabal, Ramiro ;
Arnberg, Fabian ;
Luijckx, Gert J. ;
Roberts, Robin S. ;
Schulman, Sam .
THROMBOSIS AND HAEMOSTASIS, 2014, 111 (02) :233-239
[48]   Evaluating the safety and efficacy of intravenous thrombolysis for acute ischemic stroke patients with a history of intracerebral hemorrhage: a systematic review and meta-analysis [J].
Goh, Sherill ;
Tan, Natalie H. W. ;
Tan, Choon Han ;
Leow, Aloysius S. T. ;
Sia, Ching-Hui ;
Ho, Andrew F. W. ;
Lim, Mervyn J. R. ;
Yeo, Leonard L. L. ;
Tan, Benjamin Y. Q. .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2022, 53 (02) :485-494
[49]   Prothrombin complex concentrate administration for bleeding associated with non-vitamin K antagonist oral anticoagulants: The SAMURAI-NVAF study [J].
Yoshimura, Sohei ;
Sato, Shoichiro ;
Todo, Kenichi ;
Okada, Yasushi ;
Furui, Eisuke ;
Matsuki, Takayuki ;
Yamagami, Hiroshi ;
Koga, Masatoshi ;
Takahashi, Jun C. ;
Nagatsuka, Kazuyuki ;
Arihiro, Shoji ;
Toyoda, Kazunori .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 375 :150-157
[50]   Safety and efficacy of a prothrombin complex concentrate in patients with coagulopathy and hemorrhage [J].
Martinez-Calle, N. ;
Marcos-Jubilar, M. ;
Alfonso, A. ;
Hernandez, M. ;
Hidalgo, F. ;
Lecumberri, R. ;
Paramo, J. A. .
ANALES DEL SISTEMA SANITARIO DE NAVARRA, 2014, 37 (03) :363-369